表纸
市场调查报告书

注射式药物输送设备市场:成长率,趋势,及预测(2019年 - 2024年)

Injectable Drug Delivery Devices Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品编码 871451
出版日期 内容资讯 英文 114 Pages
商品交期: 2-3个工作天内
价格
Back to Top
注射式药物输送设备市场:成长率,趋势,及预测(2019年 - 2024年) Injectable Drug Delivery Devices Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日内容资讯: 英文 114 Pages
简介

本报告提供注射式药物输送设备市场的相关调查,市场概况和成长要素、阻碍因素,各设备类型、治疗用途、地区的市场分析,竞争情形,主要企业的简介等资讯汇整。

目录

第1章 简介

  • 研究成果
  • 调查的前提条件
  • 调查范围

第2章 调查方法

第3章 摘要整理

第4章 市场动态

  • 市场概况
  • 市场成长要素
    • 慢性疾病的罹患率增加
    • 导致自行注射的需求增加的优点与便利性
    • 导致注射器的需求增加的生技药品市场成长
  • 市场阻碍因素
    • 针造成的受伤和感染
    • 替代投药法的使用扩大
  • 波特五力分析
    • 新加入厂商的威胁
    • 买主/消费者谈判力
    • 供应商谈判力
    • 替代产品的威胁
    • 产业内的竞争

第5章 市场区隔

  • 各设备类型
    • 传统的药物输送设备
    • 自我给药型药物输送设备
  • 各治疗用途
    • 循环系统疾病
    • 糖尿病
    • 肿瘤学
    • 自体免疫疾病
    • B型肝炎
    • 其他
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 中东及非洲
    • 南美

第6章 竞争情形

  • 企业简介
    • Alkermes
    • Baxter International, Inc.
    • Becton, Dickinson and Company
    • Eli Lilly and Company
    • Gerresheimer AG
    • Novartis AG
    • Pfizer, Inc.
    • Schott AG
    • Terumo Corporation
    • Teva Pharmaceutical Industries Ltd

第7章 市场机会及今后趋势

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: 52626

The injectable drug delivery devices market is expected to register a CAGR of nearly 11.5%, during the forecast period.

  • The injectable drug delivery devices market is expected to show rapid growth due to the growing burden of chronic diseases, benefits, and convenience, leading to increased demand for self injectors and growth of the biologics market, leading to increased demand for injectors.
  • The growing burden of chronic diseases has led to a rise in the overall use of syringes, particularly disposable syringes. It has been observed that most deaths by chronic diseases can be attributed to cardiovascular diseases, obesity, and diabetes. This is expected to affect the emerging countries the most, as population growth is found to be the most significant factor in developing areas.
  • A major number of drugs and therapies that address these chronic ailments are now found to be available. However, the use of syringes in the management of any chronic ailment is inevitable. Syringes can either be a part of sample collection during diagnosis or treatment regimen, like osteoarthritis. Consequently, the rise in the prevalence of chronic diseases is expected the drive the growth of the market studied.
  • Furthermore, technological advancements, improving patient compliance, beneficial reimbursement policies, and the rise of biologics in the pharmaceutical market are some of the other factors propelling the growth of the market.

Key Market Trends

Self-injectable Drug Delivery Devices is Anticipated to be Dominant during the Forecast Period

There have been boundless innovations and developments in self-injectable devices driving the growth of the market. The other major advantages associated with self-injectable injections are that they are found to be of convenient usage and low healthcare cost. These self-injectables were developed with the help of patient feedback, to provide the most adaptable devices, which have high precision of drug delivery, and are easy to use.

In addition to this, with the innovations in self-injectable devices, the acceptance of these products has increased over the past few years. Nevertheless, the advantages of self-injectable injections and increasing awareness of self-administration have helped in driving the overall market studied, during the forecast period.

The North America Region Dominates the Injectable Drug Delivery Devices Market

North America has been found dominating the injectable drug delivery devices, due to the increasing aging population and the rising number of chronic diseases that may influence the usage of injectables. According to the National Cancer Institute, 2018, there were an estimated 1,735,350 new cases of cancer that were being diagnosed in the United States. Therefore, chemotherapy drugs are being delivered to these cancer patients through injectable devices. Hence, increasing prevalence of chronic diseases and the adoption of new technologies related to injectables in the United States may help in propelling the growth of the overall market.

There are also some of the other factors that include; the large pool of patient population, increasing healthcare expenditure, rising focus of various companies, increasing healthcare awareness, and increase in government funding. Hence, all these factors are found associated with the growth of the market.

Competitive Landscape

The companies present in the market are found focusing on product innovations, expansions, finding new markets, or innovating their core competency to expand their individual market shares. There are also innovations taking place in injectable drug delivery systems that are the trend for the global injectable drug delivery market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Chronic Diseases
    • 4.2.2 Benefits and Convenience Leading to Increased Demand for Self Injectors
    • 4.2.3 Growth of the Biologics Market Leading to Increased Demand for Injectors
  • 4.3 Market Restraints
    • 4.3.1 Injuries and Infections Caused by Needles
    • 4.3.2 Growing Use of Alternative Delivery Methods
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Devices Type
    • 5.1.1 Conventional Drug Delivery Devices
    • 5.1.2 Self-injectable Drug Delivery Devices
      • 5.1.2.1 Prefilled Syringes
      • 5.1.2.2 Injectable Pens
      • 5.1.2.3 Auto Injectors
      • 5.1.2.4 Needle-free Injectors
      • 5.1.2.5 Other Device Types
  • 5.2 By Therapeutic Application
    • 5.2.1 Cardiovascular Disease
    • 5.2.2 Diabetes
    • 5.2.3 Oncology
    • 5.2.4 Autoimmune Disorders
    • 5.2.5 Hepatitis
    • 5.2.6 Other Therapeutic Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Baxter International Inc.
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 Gerresheimer AG
    • 6.1.5 Novo Nordisk A/S
    • 6.1.6 Pfizer Inc.
    • 6.1.7 Schott AG
    • 6.1.8 Terumo Corporation
    • 6.1.9 Teva Pharmaceutical Industries Ltd
    • 6.1.10 West Pharmaceutical Services Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top